Hematological PDX Models
Superior Hematological PDX Models for Better Research
Champions Oncology has established an advanced PDX platform for modeling leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and Non Hodgkins Lymphomas such as Diffuse Large B Cell Lymphoma (DLBCL) and Mantle Cell Lymphoma (MCL). This resource utilizes clinical patient samples derived directly from patients for establishing the PDX model engraftments, allowing for more realistic approach to gaining a deeper understanding of disease biology, evaluating the efficacy of novel therapeutic strategies, and modeling treatment response.
Additionally, a resource for modeling distinct treatment populations has been created by collecting blasts from patients during the course of disease progression. Both approaches provide distinct advantages:
- Studies using leukapheresis sampling allows for modeling large numbers of study mice across an established panel of patient samples. Studies using samples collected during disease progression provide for modeling defined patient cohorts co-clinically.
Correlation to Standard of Care Responses
Models treated with cytarabine show a range of responses, with a similar response rate observed in the clinic. Survival analyses can be performed, with overall survival results showing correlation to cytarabine response.